Benralizumab MEDI-563; BIW-8405|cas:1044511-01-4|西域试剂

Benralizumab MEDI-563; BIW-8405,99.1%

产品编号：Bellancom-P9923| CAS NO：1044511-01-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9923		￥8800.00	杭州北京（现货）
Bellancom-P9923		￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Benralizumab MEDI-563; BIW-8405

产品介绍

Benralizumab (MEDI-563) 是一种白介素 5 受体 α (IL-5Rα) 定向的溶细胞单克隆抗体，通过增强抗体依赖性细胞介导的细胞毒性诱导嗜酸性粒细胞直接，快速和几乎完全耗尽。Benralizumab 可用于严重的嗜酸性哮喘。

生物活性

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.

体外研究

Benralizumab (MEDI-563) binds to recombinant human and cynomolgus monkey IL-5Rα extracellular domains with a dissociation constant of 11 and 42 pM, respectively.
Benralizumab (1 pM-100 nM, 48 h) inhibits IL-5–induced proliferation of CTLL-2 cells transfected with recombinant human IL-5Rαβ with an IC₅₀ of 0.3 nM.
Benralizumab binds only to the constructs containing human IL-5Rα D1.
Benralizumab mediates ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils with EC₅₀s of 0.9 pM and 0.5 pM, respectively, and mediates eosinophil apoptosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	CTLL-2 human IL-5Rαβ cells
Concentration:	1 pM-100 nM
Incubation Time:	48 h
Result:	Inhibited cell proliferation with an IC₅₀ of 0.3 nM.

体内研究
(In Vivo)

Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female and male cynomolgus monkeys
Dosage:	0.1, 1, 10, and 30 mg/kg
Administration:	Intravenous injection, once every 3 weeks for 12 weeks
Result:	Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage.

体内研究

Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female and male cynomolgus monkeys
Dosage:	0.1, 1, 10, and 30 mg/kg
Administration:	Intravenous injection, once every 3 weeks for 12 weeks
Result:	Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage.

体内研究

Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female and male cynomolgus monkeys
Dosage:	0.1, 1, 10, and 30 mg/kg
Administration:	Intravenous injection, once every 3 weeks for 12 weeks
Result:	Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage.